Exploring the Expression of CD73 in Lung Adenocarcinoma with EGFR Genomic Alterations
CD73 expression in <i>EGFRm</i> LUAD is heterogeneous and associated with diverse TME profiles. These findings support the potential of CD73 as a predictive biomarker and therapeutic target, highlighting its clinical relevance in <i>EGFRm</i> LUAD.
Authors
- Charles‐Hugo Marquette (ORCID: https://orcid.org/0000-0002-0846-9941)
- Véronique Hofman (ORCID: https://orcid.org/0000-0003-0943-1627)
- Olivier Bordone
- Charlotte Cohen
- Christophe Bontoux (ORCID: https://orcid.org/0000-0001-5446-6197)
- Marius Ilié (ORCID: https://orcid.org/0000-0002-2014-1236)
- Élodie Long-Mira (ORCID: https://orcid.org/0000-0002-1923-6713)
- Virginie Lespinet‐Fabre
- Katia Zahaf
- Jonathan Benzaquen (ORCID: https://orcid.org/0000-0002-1899-9612)
- Valérie Vouret‐Craviari (ORCID: https://orcid.org/0000-0003-4096-5926)
- Guylène Rignol
- Jacques Boutros (ORCID: https://orcid.org/0000-0002-6468-1648)
- Christelle Bonnetaud
- Sandra Lassalle (ORCID: https://orcid.org/0000-0003-1692-2440)
- Paul M Hofman (ORCID: https://orcid.org/0000-0003-0431-9353)
- Jean‐Philippe Berthet
- Sophia Maistre
- Salomé Lalvée-Moret
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université Côte d'Azur (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Institut de Recherche sur le Cancer et le Vieillissement de Nice (FR)
- Hôpital Pasteur (FR)
Publication Details
- Journal
- Cancers
- Published
- 2025-03-20
- DOI
- https://doi.org/10.3390/cancers17061034
- Citations
- 1
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Agence Nationale de la Recherche